Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline
Open accessThe DOI matches its Crossref record; 152 of the 154 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To formulate clinical practice guidelines for the pharmacological management of obesity. PARTICIPANTS: An Endocrine Society-appointed Task Force of experts, a methodologist, and a medical writer. This guideline was co-sponsored by the European Society of Endocrinology and The Obesity Society. EVIDENCE: This evidence-based guideline was developed using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system to describe the strength of recommendations and the quality of evidence. CONSENSUS PROCESS: One group meeting, several conference calls, and e-mail communications enabled consensus. Committees and members of the Endocrine Society, the European Society of Endocrinology, and The Obesity Society reviewed and commented on preliminary drafts of these guidelines. Two systematic reviews were conducted to summarize some of the supporting evidence. CONCLUSIONS: Weight loss is a pathway to health improvement for patients with obesity-associated risk factors and comorbidities. Medications approved for chronic weight management can be useful adjuncts to lifestyle change for patients who have been unsuccessful with diet and exercise alone. Many medications commonly prescribed for diabetes, depression, and other chronic diseases have weight effects, either to promote weight gain or produce weight loss. Knowledgeable prescribing of medications, choosing whenever possible those with favorable weight profiles, can aid in the prevention and management of obesity and thus improve health.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“In contrast, the National Institute for Health and Clinical Excellence (NICE) [37], Endocrine Society [35], and American College of Cardiology [36] uniformly recommend using only licensed medications for weight management and did not consider off-label options such as metformin.”
From A systematic review of licensed weight-loss medications in treating antipsychotic-induced weight gain and obesity in schizophrenia and psychosis. (2022) · cites this paper as [35]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The STEP 1, 3, and 4 trials used semaglutide in conjunction with a lifestyle program and resulted in 16.9% to 18.2% weight-loss (using a completers-type analysis), which is superior to phase 3 trial results for other weight-loss medications, though without head-to-head drug comparison.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [759]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Commonly prescribed medications such as antidepressants (eg, mirtazapine, amitriptyline) and antihyperglycemics such as glyburide or insulin cause weight gain, and clinicians should review and consider alternatives.”
From Obesity Management in Adults: A Review (2023) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Consideration of individual food preferences, cultural traditions, and budgetary requirements may aid in the adherence to healthy dietary patterns, a key predictor of success [42,45].”
From Nutritional considerations with antiobesity medications (2024) · cites this paper as [42]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Medication classes promoting weight gain include antihyperglycemics (eg, glyburide, insulin), antidepressants (eg, amitriptyline, mirtazapine), antipsychotics (eg, olanzapine, quetiapine), antiepileptics (eg, gabapentin, carbamazepine), β-blockers, progesterone-based contraceptives, corticosteroids, and antiretroviral therapy (eg, protease inhibitors).12,77”
From Obesity Management in Adults: A Review (2023) · cites this paper as [12]
Experimental — accuracy not yet measured
29 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873 · cited 1×
“The AHA/ ACC/TOS Guideline for the Management of Overweight and Obesity in Adults reviewed randomized clinical trials on weight loss interventions and determined that the best weight loss outcomes occur with frequent face-to-face visits (16 visits per year on average) (8, 38).”
BackgroundGrading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477 · cited 1×
“The Task Force followed the approach recommended by the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) group, an international group with expertise in the development and implementation of evidence-based guidelines (1).”
MethodOverweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. Adults
Calle, E. E., Rodriguez, C., Walker-Thurmond, K., & Thun, M. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021423 · Cited by 7,696 · cited 1×
“obese are at increased risk for many malignancies (7).”
BackgroundDecision aids for people facing health treatment or screening decisions
Stacey, D., Légaré, F., Lewis, K., Barry, M. J., Bennett, C. L., Eden, K. B., Holmes-Rovner, M., Llewellyn-Thomas, H., Lyddiatt, A., Thomson, R., et al. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001431.pub5 · Cited by 6,685
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults
Jensen, M. D., Ryan, D. H., Apovian, C. M., Ard, J. D., Comuzzie, A. G., Donato, K. A., Hu, F. B., Hubbard, V. S., Jakicic, J. M., Kushner, R. F., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.004 · Cited by 4,058
Self-citationNathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Weight and Type 2 Diabetes after Bariatric Surgery: Systematic Review and Meta-analysis
Buchwald, H., Estok, R., Fahrbach, K., Banel, D., Jensen, M. D., Pories, W. J., Bantle, J. P., & Sledge, I. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2008.09.041 · Cited by 2,551 · cited 1×
“T2DM Yes Cohen, 2012 (132); Mingrone, 2012 (133); Schauer, 2012 (134); Buchwald, 2009 (135) Hypertension Yes Ilane-Parikka, 2008 (136); Phelan, 2007 (137); Zanella, 2006 (138) Dyslipidemia and metabolic syndrome Yes Ilane-Parikka, 2008 (136); Phelan, 2007 (137); Zanella, 2006 (138) Cardiovascular disease Yes Wannameth…”
Central nervous system control of food intake and body weight
Morton, G. J., Cummings, D. E., Baskin, D. G., Barsh, G. S., & Schwartz, M. W. (2006) · Nature · doi:10.1038/nature05026 · Cited by 2,503 · cited 1×
“GLP-1 agonists also affect the POMC neurons and cause satiety (18).”
Background
Research works printed but not linked: 15
- [3]3. DomecqJP,PrutskyG,LeppinA,etal. Drugscommonlyassociated with weight change: a systematic review and meta-analysis. J Clin Endocrinol Metab . 2015;100:363-370.
- [11]11. Goldsmith R, Joanisse DR, Gallagher D, et al. Effects of experimentalweightperturbationonskeletalmuscleworkefficiency,fuel utilization, and biochemistry in human subjects. Am J Physiol Regul Integr Comp Physiol . 2010;298:R79-R88.
- [19]19. Stahl SM. Impulsivity, compulsivity, and addiction. In: Stahl's Essential Psychopharmacology . 4th ed. New York, NY: Cambridge University Press; 2013:537-575.
- [22]22. Mendieta-ZerónH,LópezM,DiéguezC. Gastrointestinalpeptides controlling body weight homeostasis. Gen Comp Endocrinol . 2008;155:481-495.
- [35]35. Avenell A, Brown TJ, McGee MA, et al. Whatinterventions should weaddtoweightreducingdietsinadultswithobesity?Asystematic review of randomized controlled trials of adding drug therapy, exercise, behaviourtherapyorcombinationsoftheseinterventions. J Hum Nutr Diet . 2004;17:293-316.
- [68]68. Grandy S, Hashemi M, Langkilde AM, Parikh S, Sjöström CD. Changesinweightloss-related quality of life among type 2 diabetes mellitus patients treated with dapagliflozin. Diabetes Obes Metab . 2014;16:645-650.
- [79]79. Greenway FL, Fujioka K, Plodkonski RA, et al. COR I Study Group. Lancet . 2010;376:595-605.
- [82]82. Jacob AN, Salinas K, Adams-Huet B, Raskin P. Weightgainintype 2 diabetes mellitus. Diabetes Obes Metab . 2007;9:386-393.
- [88]88. Mäkimattila S, Nikkilä K, Yki-Järvinen H. Causes of weight gain duringinsulintherapywithandwithoutmetformininpatientswith type II diabetes mellitus. Diabetologia . 1999;42:406-412.
- [95]95. WingLM,ReidCM,RyanP,etal. Acomparisonofoutcomeswith angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med . 2003;348:583-592.
- [110]110. MaayanL,CorrellCU. Weightgainandmetabolicrisks associated withantipsychoticmedicationsinchildrenandadolescents. J Child Adolesc Psychopharmacol . 2011;21:517-535.
- [126]126. Boers M, van der Heijde DM. Prevention or retardation of joint damageinrheumatoidarthritis:issuesofdefinition,evaluationand interpretation of plain radiographs. Drugs . 2002;62(12):17171724.
- [128]128. Aronne LJ. Drug-induced weight gain: non-CNS medications. In: Aronne LJ, ed. A Practical Guide to Drug-Induced Weight Gain . Minneapolis, MN: McGraw-Hill; 2002:77-91.
- [14]14. tional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study. Am J Gastroenterol . 2005;100:1072-1081.
- [146]146. Huang MH, Chen CH, Chen TW, Weng MC, Wang WT, Wang YL. Theeffectsofweightreductionontherehabilitationofpatients with knee osteoarthritis and obesity. Arthritis Care Res . 2000;13: 398-405.
Cited by
Items 701–800 of 1,001
Álvarez, J., Escribano, P., & Trifu, D. S. (2016) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2016.12.002 · Cited by 13
Kozica, S. L., Teede, H. J., Harrison, C. L., Klein, R. A., & Lombard, C. B. (2015) · The Journal of Rural Health · doi:10.1111/jrh.12133 · Cited by 9
“At the individual level, weight gain prevention requires only minor lifestyle adjustments and does not include adaptive changes which drive weight regain.(4) At the organizational level, prevention programs have the potential to reduce health care costs and have broader population reach in comparison to obesity treatm…”
BackgroundObesity: A Growing Multifaceted Problem
Azevedo, P. S., Minicucci, M. F., & Zornoff, L. A. M. (2015) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20150133 · Cited by 10
Serrano, J., Casanova‐Martí, À., Blay, M., Terra, X., Pinent, M., & Ardèvol, A. (2017) · Trends in Food Science & Technology · doi:10.1016/j.tifs.2017.08.002 · Cited by 10
Medicinal plants having anti-obesity potentiality available in Bangladesh: A review.
Rahman, A. M., & Rahman, M. M. (2018) · doi:10.35841/biology-medicine.2.1.4-11 · Cited by 7
“There are numerous complementary and integrative practices, including physical activity, dietary programs, surgical interventions, behavioral ther apy, lifestyle modifications, medicinal therapies and the use of medicinal plants [5-10].”
BackgroundTaylor, J. (2019) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2019.09.021 · Cited by 11
Moringa Oleifera improve lipid metabolic disorders in obesity induced oxidative stress in rats
Hussein, S. A., Elsenosi, Y. A., & Ghada, H. E.-S. (2018) · Benha Veterinary Medical Journal · doi:10.21608/bvmj.2018.96443 · Cited by 7
“…Management of Obesity: An Endocrine Society Clinical Practice (ESCP) Guideline”, recommended by the National Heart, Lung, and Blood Institute (Apovian et al., 2015) the most ideal treatment modality for weight loss should be appropriate dietary and lifestyle changes plus moderate-intensity…”
MethodInfluentialPerna, S., Basharat, S., Ali, K. F., Eid, A., Gasparri, C., Infantino, V., Faliva, M. A., Naso, M., Cazzola, R., Cestaro, B., et al. (2020) · Nutrients · doi:10.3390/nu12082365 · Cited by 7
“In particular, the guidelines state that drugs may amplify adherence to behavior change and may improve physical functioning as increased physical activity is easier in those who cannot exercise initially [3,4].”
BackgroundEffectiveness of Deep Brain Stimulation in Reducing Body Mass Index and Weight: A Systematic Review
López, W. O. C., Navarro, P. A., & Crispín, S. (2021) · Stereotactic and Functional Neurosurgery · doi:10.1159/000519158 · Cited by 10
Carreira, M. C., Andrade, S., Izquierdo, A. G., Amil, M., Folgueira, C., Monteiro, M. P., Sanz, E., Crujeiras, A. B., & Casanueva, F. F. (2018) · Scientific Reports · doi:10.1038/s41598-018-34840-7 · Cited by 7
Identifying and Treating Nonalcoholic Fatty Liver Disease.
Hunt, C. M., Turner, M. J., Gifford, E. J., Britt, R. B., & Su, G. L. (2019) · Europe PMC (PubMed Central) · Cited by 9
GLP-1RAs for the treatment of obesity in women after menopause
Paschou, S. Α., Kotsa, K., Peppa, Μ., Hatziagelaki, E. E., & Ψαλτοπούλου, Θ. (2021) · Maturitas · doi:10.1016/j.maturitas.2021.12.003 · Cited by 8
Building a Medical–Surgical Obesity Center in an Academic Health System: Lessons Learned
Davisson, L., Haggerty, T. S., Tabone, L. E., Imlay, R. K., & Eggleston, E. (2022) · Bariatric Surgical Practice and Patient Care · doi:10.1089/bari.2022.0028 · Cited by 6
Management of Medication-Induced Weight Gain
Barenbaum, S. R., Kumar, R. B., & Aronne, L. J. (2023) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2023.08.006 · Cited by 6
Self-citationThe weight reduction mediated by anti-obesity medication and the cardiovascular outcome
Guo, Y., Chu, L., Cai, X., Wu, H., Yan, J., Li, Z., Jiao, R., Bai, S., Yang, W., Lv, F., et al. (2024) · iScience · doi:10.1016/j.isci.2024.110867 · Cited by 6
“6 Anti-obesity medications (AOMs), as an important treatment for obesity, 7 could achieve certain weight reduction in patients with over-weight or obesity, but their cardiovascular effects still remain to be unclear.”
Weight Loss Intentionality and Frailty are Associated with Pre–Kidney Transplant Outcomes
Ghildayal, N., Hong, J., Liu, Y., Li, Y., Cockey, S. G., Ali, N. M., Mathur, A., Orandi, B. J., Segev, D. L., & McAdams‐DeMarco, M. (2024) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000604 · Cited by 6
“…or had obesity ( i.e ., with a BMI $ 27 kg/m 2 because this cutoff is the indication for weight loss medication in patients with ESKD) 37,38 and ( 2 ) limiting to candidates ( N 5 601 participants who were evaluated for KT and N 5 367 who were listed for KT) who had more severe obesity…”
Wang, J., Lin, C., Cai, X., Wang, Y., Wei, T., Wang, Y., Tie, C., Yang, Y., Lv, F., Yang, W., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16552 · Cited by 7
Osborne, D., & Abdelgadir, E. (2026) · International Journal of Obesity · doi:10.1038/s41366-025-02002-1 · Cited by 9
Blockbuster Medications for Obesity: A Primer for Nephrologists
Zeitler, E. M., Dabb, K., Nadeem, D., Still, C. D., & Chang, A. R. (2023) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2023.04.009 · Cited by 6
Self-citationElfers, C., Chichura, K. S., Ashlaw, E. F., Chepurny, O. G., Holz, G. G., Doyle, R. P., & Roth, C. L. (2024) · Clinical Nutrition · doi:10.1016/j.clnu.2024.05.035 · Cited by 8
Cross, L. V. (2024) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxae273 · Cited by 8
Decoding Obesity Management Medications and the Journey to Informed Treatment Choices for Patients
Koball, A. M., Ames, G. E., Grothe, K. B., Clark, M. M., Collazo–Clavell, M. L., & Elli, E. F. (2024) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2024.10.003 · Cited by 6
Medical Management of Obesity: Current Trends and Future Perspectives
Calderón, A., Aguilera-Astudillo, M., Rojas, A. P., Dowlatshahi, S., Kansara, A., Shakil, J., & Patham, B. (2025) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcvj.1503 · Cited by 8
Vargas, E. J., Bazerbachi, F., Storm, A. C., Rizk, M., Acosta, A. J., Grothe, K. B., Clark, M. M., Mundi, M. S., Pesta, C. M., Bali, A. H., et al. (2019) · Obesity Surgery · doi:10.1007/s11695-019-04102-0 · Cited by 7
Bourke, M., Patel, D., Rocca, A., Maric, T., & Savvidou, M. D. (2021) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2021.04.015 · Cited by 6
Nuijten, M. J. C., Dainelli, L., Rasouli, B. S., Torres, K. A., Perugini, M., & Marczewska, A. M. (2021) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s284855 · Cited by 8
Weight gain after in vitro fertilization: a potential consequence of controlled ovarian stimulation
Bajaj, S. S., Jain, B., & Stanford, F. C. (2022) · Journal of Assisted Reproduction and Genetics · doi:10.1007/s10815-022-02444-w · Cited by 6
Gasparri, C., Perna, S., Peroni, G., Riva, A., Petrangolini, G., Faliva, M. A., Naso, M., & Rondanelli, M. (2022) · Eating and Weight Disorders - Studies on Anorexia Bulimia and Obesity · doi:10.1007/s40519-022-01412-8 · Cited by 5
“Pharmacological therapy is indicated only in case of BMI > 30 kg/m2 or BMI > 27 kg/m2 in the presence of comorbidities [12].”
BackgroundKhalafi, M., & Symonds, M. E. (2022) · Science & Sports · doi:10.1016/j.scispo.2022.01.007 · Cited by 7
Overweight and Obesity Management for Primary Care Clinicians: Executive Summary
Anderson, J. E., Kushner, R. F., Miller, E. M., Nadglowski, J. F., & Still, C. D. (2022) · Clinical Diabetes · doi:10.2337/cd22-0082 · Cited by 10
Self-citationGastroesophageal Reflux Disease and Obesity
Wibawa, I. D. N., & Dharmesti, N. W. W. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.106528 · Cited by 6
Ağbaht, K., & Pişkinpaşa, S. (2022) · BMC Endocrine Disorders · doi:10.1186/s12902-022-01202-4 · Cited by 7
Ana, C. T. S., Costa, N. M. B., Martino, H. S. D., & de Barros, F. A. R. (2023) · Research Society and Development · doi:10.33448/rsd-v12i2.39223 · Cited by 12
“3 Correlation between main properties and potential health benefits Non-communicable chronic diseases such as obesity, diabetes, metabolic syndrome, among others, are currently a major public health problem and have a great impact at an economic and social level (Apovian et al. 2015).”
Cuzzolaro, M. (2015) · Springer eBooks · doi:10.1007/978-3-319-24532-4_8 · Cited by 8
Vesely, J. M., Pronk, N. P., Kottke, T. E., & Marshall, P. S. (2016) · Current Obesity Reports · doi:10.1007/s13679-016-0220-0 · Cited by 7
Lu, T., Chiu, H., Chen, Y., Shen, Y., Han, Y., Venkatakrishnan, K., & Wang, C. (2019) · Food & Function · doi:10.1039/c9fo00192a · Cited by 10
Saxon, D. R., Chaussee, E. L., Juarez‐Colunga, E., Tsai, A. G., Iwamoto, S. J., Speer, R. B., Heyn, H., Kealey, E. H., & Bessesen, D. H. (2019) · Journal of General Internal Medicine · doi:10.1007/s11606-019-05222-0 · Cited by 7
Self-citationCurrent and Future Medical Treatment of Obesity
Umashanker, D., Igel, L. I., Kumar, R. B., & Aronne, L. J. (2017) · Gastrointestinal Endoscopy Clinics of North America · doi:10.1016/j.giec.2016.12.008 · Cited by 6
“Phentermine is primarily a noradrenergic and possibly dopaminergic sympathomimetic amine.(46) The standard adult dose is up to 37.”
BackgroundSelf-citationPaediatric obesity: can medications help
Lenders, C. M. (2015) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000183 · Cited by 6
Clinical interventions to break the obesity and cancer link: a narrative review
Bhardwaj, N. J., Chae, K., Sheng, J. Y., & Yeh, H.-C. (2022) · Cancer and Metastasis Reviews · doi:10.1007/s10555-022-10055-1 · Cited by 5
Review of Pharmacologic Weight Loss Medications in a Patient-Centered Medical Home
Costello, T., Dorrell, M., Kellams, T., & Kraska, K. (2016) · Journal of Pharmacy Technology · doi:10.1177/8755122515604858 · Cited by 5
“Many risks are associated with obesity such as morbidity and mortality from hypertension, dyslipidemia, type 2 diabetes mellitus, coronary heart disease, stroke, gallbladder disease, osteoarthritis, sleep apnea, respiratory problems, and cancer.(1,2) With the overwhelming number of obese adults determined in 2009, it…”
BackgroundInfluentialSrivastava, G., Campbell, S. L., Hill, C. R., Stanley, T. L., Lawson, E. A., Apovian, C. M., Almandoz, J. P., Leggio, L., Lakdawalla, D. N., Dar, M., et al. (2025) · The American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2025.06.015 · Cited by 5
“40.0) [126,127].”
InfluentialSelf-citationContraceptive Selection for the Endocrine Patient: What an Endocrinologist Should Know
Zaman, A., Lazorwitz, A. M., & Wierman, M. E. (2025) · Endocrine Reviews · doi:10.1210/endrev/bnaf016 · Cited by 9
Polu, P. R. (2026) · Obesity Medicine · doi:10.1016/j.obmed.2026.100686 · Cited by 7
Overview of Metabolic Syndrome
Ahima, R. S. (2023) · Springer eBooks · doi:10.1007/978-3-031-40116-9_1 · Cited by 12
Role of pharmacists in the management of patients with obesity
Jovanović, M., Kovačević, M., & Ćulafić, M. (2024) · Arhiv za farmaciju · doi:10.5937/arhfarm74-50561 · Cited by 6
Advancements in Understanding and Preventing Obesity-Related Colon Cancer
Shieh, C., Thompson, H. J., McLaughlin, E. M., Chiang, C., & Hussan, H. (2024) · The Cancer Journal · doi:10.1097/ppo.0000000000000744 · Cited by 5
Pharmacologic Therapy of Obesity
Primack, C. (2024) · Springer eBooks · doi:10.1007/978-3-031-70004-0_5 · Cited by 5
Lim, S. K., Nam, G. E., & Sharma, A. M. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0278 · Cited by 6
“These interventions often lack rigorous scientific validation and are marketed directly to consumers with exaggerated claims and minimal regulatory scrutiny [12,50].”
InfluentialMartínez, J. J. G. (2016) · Medicina Clínica · doi:10.1016/s0025-7753(17)30619-x · Cited by 8
Discovery of a novel anti-obesity meroterpenoid agent targeted subcutaneous adipose tissue
Chen, B., Shi, Z., Wang, Y., Chen, M., Yang, C., Cui, H., Su, T., & Kwan, H. Y. (2022) · Phytomedicine · doi:10.1016/j.phymed.2022.154396 · Cited by 5
Obesity Epidemic in U.S. Prison Populations: A Meta-Analysis and Review of the Literature
Davis, D., Wilson, L., Salas, J., & Gilman, R. H. (2023) · Journal of Correctional Health Care · doi:10.1089/jchc.21.06.0055 · Cited by 5
“Obesity is associated with dozens of health complications, including worse outcomes in SARS-CoV-2 infections (Apovian et al. , 2015; Field et al. , 2001; Herbert et al. , 2012; Jensen et al. , 2014; Kwok et al. , 2020; Leddy et al. , 2009; Mitchell & Shaw, 2015), and there is evidence that pris-ons…”
Choi, W. J., Kim, M. H., Park, N., Chung, J. Y., Park, S. J., & Yang, W. M. (2023) · Integrative Medicine Research · doi:10.1016/j.imr.2023.100948 · Cited by 7
Xue, Y., Ruan, Z., Ung, C. O. L., Lai, Y., & Hu, H. (2023) · BMC Public Health · doi:10.1186/s12889-023-15890-7 · Cited by 7
Does liraglutide alleviate inflammation in brain-dead donors? A randomized clinical trial
Custódio, G., Massutti, A. M., da Igreja, M. R., Lemos, N. E., Crispim, D., Visioli, F., Palma, V. D. M., Leitão, C. B., & Rech, T. H. (2023) · Liver Transplantation · doi:10.1097/lvt.0000000000000298 · Cited by 6
“[11,12] Although liraglutide, another GLP-1 analogue, is an FDA-approved drug for treating type 2 diabetes and obesity, [13 – 15] its anti-inflammatory and antiapoptotic properties have not been studied in reducing inflammation, endoplasmic reticulum stress, and oxidative stress of organs from…”
BackgroundImplementation of a pharmacist-led weight loss service to improve medication access and weight loss
Schermerhorn, S., Aurora, J. A., McElligott, M., & Siegel, R. D. (2024) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2024.102085 · Cited by 6
Current and Emerging Parenteral and Peroral Medications for Weight Loss: A Narrative Review
Lawati, A. A., Alhabsi, A. N., Rahul, R., Savino, M.-L., Alwahaibi, H., Das, S., & Lawati, H. A. (2025) · Diseases · doi:10.3390/diseases13050129 · Cited by 6
Lifestyle Therapy for Diabetes Mellitus
Garvey, W. T., & Arathuzik, G. (2016) · Springer eBooks · doi:10.1007/978-3-319-24687-1_22 · Cited by 8
Diethylpropion and mazindol: An end to the discussion?
Lucchetta, R. C., Riveros, B. S., Pontarolo, R., Radominski, R. B., Otuki, M. F., Fernández-Llimós, F., & Correr, C. J. (2017) · Revista da Associação Médica Brasileira · doi:10.1590/1806-9282.63.03.203 · Cited by 5
“The heterogeneity statistic I(2) can be biased in small metaanalyses.”
BackgroundPharmacokinetic drug evaluation of extended release lorcaserin for the treatment of obesity
Hurren, K. M., & Dunham, M. W. (2017) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2017.1344214 · Cited by 5
Londoño-Lemos, M. E., Martínez-Bulit, P., López-Sandoval, H. C., Gracia‐Mora, I., Sánchez‐Bartéz, F., Castro-Jiménez, T. K., Duarte-Hernández, A. M., Flores‐Parra, A., Contreras, R., & Barba-Behrens, N. (2017) · Transition Metal Chemistry · doi:10.1007/s11243-017-0163-7 · Cited by 5
Weight Management Practices Among Florida Nurse Practitioners: A Cross-Sectional Study
Hyer, S., & Edwards, J. B. (2019) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2019.10.025 · Cited by 6
Gao, Y., Xu, S., Shen, Y., Liao, T., Hu, S., Zhou, S., & Chen, Q. (2020) · Medicine · doi:10.1097/md.0000000000019683 · Cited by 6
Identifying characteristics and outcomes in youth with obesity and developmental disabilities
Rubin, M. B., Miller, C. M., Bauer, S. C., Ariza, A. J., & Binns, H. J. (2020) · Disability and health journal · doi:10.1016/j.dhjo.2020.100988 · Cited by 5
Peña, I. D., Figueroa, J. D., & Shi, W. (2022) · Pharmacology Research & Perspectives · doi:10.1002/prp2.947 · Cited by 5
Pasado, presente y futuro de la farmacoterapia para la obesidad
Benaiges, D., Pedro‐Botet, J., Roux, J. A. F., Climent, E., & Goday, A. (2017) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2017.06.002 · Cited by 9
Su, W., Chen, F., Dall, T. M., Zvenyach, T., Kyle, T. K., & Perreault, L. (2018) · Journal of Medical Economics · doi:10.1080/13696998.2018.1496922 · Cited by 5
Current Endoscopic/Laparoscopic Bariatric Procedures
Mathus-Vliegen, E. M. H., & Dargent, J. (2018) · Springer eBooks · doi:10.1007/978-3-319-90074-2_2 · Cited by 8
Safavi, R., Lih, A., Kirkpatrick, S. M., Haller, S., & Bailony, M. R. (2019) · Obesity Science & Practice · doi:10.1002/osp4.361 · Cited by 6
Song, J., Shin, S.-M., & Kim, H. (2019) · Medicine · doi:10.1097/md.0000000000017922 · Cited by 5
“These drugs are intended for moderately and severely obese patients with a BMI ≥30 or a BMI ≥27 with comorbidities and are associated with a high incidence of side effects.([3]) As alternatives to these medications, complementary and alternative treatments, such as herbs and acupuncture, have gained increasing popular…”
BackgroundPast, present and future of pharmacotherapy for obesity
Benaiges, D., Pedro‐Botet, J., Roux, J. A. F., Climent, E., & Goday, A. (2017) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2017.06.003 · Cited by 8
Pharmacologic Agents Chapter for Abdominal Obesity
Nuffer, W. A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816093-0.00005-7 · Cited by 8
Hauner, H. (2016) · Wiley eBooks · doi:10.1002/9781118924853.ch16 · Cited by 12
Herges, J. R., Neumiller, J. J., & McCoy, R. G. (2025) · Clinical Diabetes · doi:10.2337/cd24-0115 · Cited by 5
Cetiner, S. (2026) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s594898 · Cited by 7
Should family physicians prescribe medication for obesity? YES.
Bourns, L., & Shiau, J. Y. (2017) · Europe PMC (PubMed Central) · Cited by 4
Arabpour, E., Golmoradi, H., Tape, P. M. K., Sadeghi, A., Abdehagh, M., Moghadam, P. K., & Zali, M. R. (2024) · Clinical Endoscopy · doi:10.5946/ce.2024.153 · Cited by 5
How do patients choose between obesity medications: A thematic analysis
Mondoh, A., Craig, H. C., Crotty, M., Contreras, F., & le Roux, C. W. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100187 · Cited by 6
“Thematic analysis was conducted both inductively (allowed themes to emerge from the data itself) and deductively (guided by pre-existing theoretical frameworks, such as the Health Belief Model [6].”
Exosomes and microRNAs: Molecular Mediators Linking Obesity, Exercise, and Metabolic Regulation
Joaquim, V. H. A., Pereira, N. P., Caria, A. C. I., Pelozin, B. R. D. A., Fernandes, T. M., & de Oliveira, E. M. (2025) · Current Diabetes Reports · doi:10.1007/s11892-025-01608-z · Cited by 6
“Despite the availability of these medications, their long-term efficacy is often limited by side effects, poor adherence, and weight regain [ 149 ].”
Alawami, F., Novaes, O., Gibney, J., Phelan, N., Behan, L., & Owens, L. A. (2025) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-025-04194-x · Cited by 7
Qi, H., Zhang, Z., Hou, T., Ding, L., Liu, Q., Wang, Y., Song, S., Liu, J., Sun, C., Sun, Y., et al. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.157750 · Cited by 4
Strathe, A., Bomberg, E. M., Jensch, G., Kildegaard, J., Harder-Lauridsen, N. M., Weghuber, D., & Overgaard, R. V. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70678 · Cited by 4
Wang, Y., Liu, J., Verbeke, K., Gasaly, N., Akkerman, R., & de Vos, P. (2026) · Advances in Nutrition · doi:10.1016/j.advnut.2026.100647 · Cited by 11
“If the response is suboptimal, sequential addition of a GLP-1RA can promote further weight reduction [150].”
Acevedo-Pacheco, L., de la Garza, A. R. M., Palacios, E., Gutierrez-Uribe, J. A., Trejo-Chávez, A., Cruz‐Suárez, L. E., & Serna-Saldivar, S. O. (2020) · Algal Research · doi:10.1016/j.algal.2020.101946 · Cited by 5
Liu, J., Liu, S., Fu, G., Qiu, X., Jiang, R., Huang, S.-Y., Zhu, L., & Li, W. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.714643 · Cited by 4
Huerta‐Cruz, J. C., Rocha-González, H. I., Kammar‐García, A., Canizales‐Quinteros, S., Barranco‐Garduño, L. M., & Reyes-García, J. G. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11113211 · Cited by 4
Social media for obesity education: a general overview for the novice creator
Sobel, S. I., & Dubé, J. J. (2024) · AJP Advances in Physiology Education · doi:10.1152/advan.00120.2023 · Cited by 6
Aladenika, Y. V., Akinjiyan, M. O., Elekofehinti, O. O., & Adanlawo, I. G. (2024) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2024.119116 · Cited by 5
Role of Microneedles for Improved Treatment of Obesity: Progress and Challenges
Chilamakuri, S. N., Manasa, N., Thalla, M., Ravichandiran, V., Lee, Y., Cho, S. M., Jung, H., & Natesan, S. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c01115 · Cited by 5
Treating obesity to optimize women’s health outcomes
Rubino, D., & Schon, S. B. (2025) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000002595 · Cited by 4
Effect of weight loss through dietary interventions on cardiometabolic health in older adults
Dhana, K., Aggarwal, N. T., Voigt, R. M., Ventrelle, J., Rajan, K. B., Kaddurah‐Daouk, R., Marcovina, S. M., Liu, X., Agarwal, P., Tangney, C., et al. (2025) · International Journal of Obesity · doi:10.1038/s41366-025-01902-6 · Cited by 7
“These strategies include lifestyle modi fi cations [6 – 11], pharmacological therapies [12, 13], and bariatric surgery [14].”
Obesity Context of Type 2 Diabetes and Medication Perspectives
Pandit, A., & Pandey, A. K. (2016) · Apollo Medicine · doi:10.1016/j.apme.2015.08.001 · Cited by 4
Smetana, G. W., Jones, D. B., & Wee, C. C. (2017) · Annals of Internal Medicine · doi:10.7326/m17-0698 · Cited by 5
ASGE EndoVators Summit: Defining the role and value of endoscopic therapies in obesity management
Ryou, M. K., McQuaid, K. R., Thompson, C. C., Edmundowicz, S. A., Mergener, K., Dayyeh, B. A., Apovian, C. M., Burke, C. A., Chand, B., Chandraker, A. K., et al. (2017) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2017.08.024 · Cited by 7
Self-citationTsai, A. G. (2019) · The Permanente Journal · doi:10.7812/tpp/18-240 · Cited by 4
Игоревна, К. П., Logvinova, O., Poydasheva, A. G., Kremneva, E. I., Bakulin, I. S., Раскуражев, А. А., Лагода, О. В., Suponeva, N. A., Troshina, E. A., Tanashyan, M. М., et al. (2020) · Obesity and metabolism · doi:10.14341/omet10148 · Cited by 4
Extrapolation from Clinical Trial to Practice: Current Pharmacotherapy on Obesity
Gorain, B., Choudhury, H., Sengupta, P., Verma, R. K., & Pandey, M. (2021) · Springer eBooks · doi:10.1007/978-981-33-6408-0_10 · Cited by 4
Management of Obesity During Pregnancy and Periconception: Case-Based Learning for OB/GYN Clerkships
Cook, J., Puckett, H. L., & Steinauer, J. E. (2021) · MedEdPORTAL · doi:10.15766/mep_2374-8265.11129 · Cited by 5
Promising areas of pharmacotherapy for obesity
Druzhilov, М. A., Kuznetsova, Т. Y., & Chumakova, G. A. (2021) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2021-4279 · Cited by 4
Evaluation of Pharmacologic Interventions for Weight Management in a Veteran Population
Hood, S., Berkeley, A. W., & Moore, E. A. (2021) · Federal Practitioner · doi:10.12788/fp.0117 · Cited by 4
Metadata
- Authors
- Apovian, C. M., Aronne, L. J., Bessesen, D. H., McDonnell, M. E., Murad, M. H., Pagotto, U., Ryan, D. H., & Still, C. D.
- Affiliations
- Pennington Biomedical Research Center (US)
- Cornell University (US)
- Denver Health Medical Center (US)
- Brigham and Women's Hospital (US)
- Mayo Clinic (US)
- IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola (IT)
- Geisinger Health System (US)
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2015-02
- Volume
- 100
- Issue
- 2
- Pages
- 342-362
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2109366467
- Semantic Scholar
- 32e063efbad03793d5b9794138fe9a8f9b3a4650
- Cited by
- 1,347
- References
- 154
- Citations by year
- 2026: 109 · 2025: 128 · 2024: 157 · 2023: 134 · 2022: 112 · 2021: 129 · 2020: 132 · 2019: 98 · 2018: 91 · 2017: 102 · 2016: 95 · 2015: 55
- FWCI
- 82.37
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion, cc-by-nc-nd)
- INFM-OAR (INFN Catania) (submittedVersion, other-oa)
- Zenodo (CERN European Organization for Nuclear Research) (cc-by)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Obesity, Physical Activity, Diet
- Keywords
- obesity, anti-obesity drugs, weight loss, lifestyle modification, obesity-related comorbidities, medication-induced weight gain, drug prescribing, chronic disease medications
- MeSH terms
- Endocrinology, Humans, Obesity, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.